: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

Oliena Studio

Stroke and language recovery: 9000+ videos

Español • Italiano • Sardu • English | PDF+

Autoimmune Disorders

Free Subscription

Articles published in Mult Scler
Retrieve available abstracts of 428 articles:
HTML format
Text format

Single Articles

May 2019

AHRWEILLER K, Rousseau C, Le Page E, Bajeux E, et al
Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis.
Mult Scler. 2019 May 16:1352458519848090. doi: 10.1177/1352458519848090.
PubMed Text format Abstract available

MURPHY OC, Kwakyi O, Iftikhar M, Zafar S, et al
Alterations in the retinal vasculature occur in multiple sclerosis and exhibit novel correlations with disability and visual function measures.
Mult Scler. 2019 May 16:1352458519845116. doi: 10.1177/1352458519845116.
PubMed Text format Abstract available

PUGLIATTI M
Changes in the sex ratio are a good indicator of changes in multiple sclerosis incidence - Commentary.
Mult Scler. 2019 May 15:1352458519845114. doi: 10.1177/1352458519845114.
PubMed Text format

KOPP TI, Blinkenberg M, Chalmer TA, Petersen T, et al
Predictors of treatment outcome in patients with paediatric onset multiple sclerosis.
Mult Scler. 2019 May 13:1352458519846100. doi: 10.1177/1352458519846100.
PubMed Text format Abstract available

CONTE A, Gianni C, Belvisi D, Cortese A, et al
Deep grey matter involvement and altered sensory gating in multiple sclerosis.
Mult Scler. 2019 May 13:1352458519845287. doi: 10.1177/1352458519845287.
PubMed Text format Abstract available

FITZGERALD KC, Salter A, Tyry T, Fox RJ, et al
Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis.
Mult Scler. 2019 May 13:1352458519845836. doi: 10.1177/1352458519845836.
PubMed Text format Abstract available

MOSS BP, Cohen JA
The emergence of follow-on disease-modifying therapies for multiple sclerosis.
Mult Scler. 2019 May 10:1352458519845106. doi: 10.1177/1352458519845106.
PubMed Text format Abstract available

TUR C, Grussu F, Prados F, Charalambous T, et al
A multi-shell multi-tissue diffusion study of brain connectivity in early multiple sclerosis.
Mult Scler. 2019 May 10:1352458519845105. doi: 10.1177/1352458519845105.
PubMed Text format Abstract available

FALET JR, Deshmukh S, Al-Jassim A, Sigler G, et al
The neurologist's role in disabling multiple sclerosis: A qualitative study of patient and care provider perspectives.
Mult Scler. 2019 May 10:1352458519845107. doi: 10.1177/1352458519845107.
PubMed Text format Abstract available

April 2019

PHELPS R, Winston JA, Wynn D, Habek M, et al
Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.
Mult Scler. 2019 Apr 15:1352458519841829. doi: 10.1177/1352458519841829.
PubMed Text format Abstract available

BARLETTA VT, Herranz E, Treaba CA, Ouellette R, et al
Evidence of diffuse cerebellar neuroinflammation in multiple sclerosis by (11)C-PBR28 MR-PET.
Mult Scler. 2019 Apr 11:1352458519843048. doi: 10.1177/1352458519843048.
PubMed Text format Abstract available

VUKUSIC S, Coyle PK, Jurgensen S, Truffinet P, et al
Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience.
Mult Scler. 2019 Apr 10:1352458519843055. doi: 10.1177/1352458519843055.
PubMed Text format Abstract available

BROWN JWL, Chowdhury A, Kanber B, Prados Carrasco F, et al
Magnetisation transfer ratio abnormalities in primary and secondary progressive multiple sclerosis.
Mult Scler. 2019 Apr 8:1352458519841810. doi: 10.1177/1352458519841810.
PubMed Text format Abstract available

BANWELL B
Are children with multiple sclerosis really "old" adults.
Mult Scler. 2019 Apr 4:1352458519841505. doi: 10.1177/1352458519841505.
PubMed Text format

BARTELS F, Nobis K, Cooper G, Wendel E, et al
Childhood multiple sclerosis is associated with reduced brain volumes at first clinical presentation and brain growth failure.
Mult Scler. 2019 Apr 4:1352458519829698. doi: 10.1177/1352458519829698.
PubMed Text format Abstract available

March 2019

HYUN JW, Kim Y, Kim G, Kim SH, et al
Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis.
Mult Scler. 2019 Mar 26:1352458519840757. doi: 10.1177/1352458519840757.
PubMed Text format Abstract available

BOONSTRA FM, Noffs G, Perera T, Jokubaitis VG, et al
Functional neuroplasticity in response to cerebello-thalamic injury underpins the clinical presentation of tremor in multiple sclerosis.
Mult Scler. 2019 Mar 25:1352458519837706. doi: 10.1177/1352458519837706.
PubMed Text format Abstract available

BAGNATO F, Franco G, Ye F, Fan R, et al
Selective inversion recovery quantitative magnetization transfer imaging: Toward a 3 T clinical application in multiple sclerosis.
Mult Scler. 2019 Mar 25:1352458519833018. doi: 10.1177/1352458519833018.
PubMed Text format Abstract available

D'AMBROSIO A, Valsasina P, Gallo A, De Stefano N, et al
Reduced dynamics of functional connectivity and cognitive impairment in multiple sclerosis.
Mult Scler. 2019 Mar 19:1352458519837707. doi: 10.1177/1352458519837707.
PubMed Text format Abstract available

RUSSO CV, Sacca F, Paternoster M, Buonomo AR, et al
Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis.
Mult Scler. 2019 Mar 18:1352458518813110. doi: 10.1177/1352458518813110.
PubMed Text format

MEYER CE, Gao JL, Cheng JY, Oberoi MR, et al
Axonal damage in spinal cord is associated with gray matter atrophy in sensorimotor cortex in experimental autoimmune encephalomyelitis.
Mult Scler. 2019 Mar 7:1352458519830614. doi: 10.1177/1352458519830614.
PubMed Text format Abstract available

STRAUDI S, Manfredini F, Lamberti N, Martinuzzi C, et al
Robot-assisted gait training is not superior to intensive overground walking in multiple sclerosis with severe disability (the RAGTIME study): A randomized controlled trial.
Mult Scler. 2019 Mar 4:1352458519833901. doi: 10.1177/1352458519833901.
PubMed Text format Abstract available

February 2019

PALMER AJ, van der Mei I, Taylor BV, Clarke PM, et al
Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia.
Mult Scler. 2019 Feb 26:1352458519831213. doi: 10.1177/1352458519831213.
PubMed Text format Abstract available

URRU SA, Antonelli A, Sechi GM
Prevalence of multiple sclerosis in Sardinia: A systematic cross-sectional multi-source survey.
Mult Scler. 2019 Feb 22:1352458519828600. doi: 10.1177/1352458519828600.
PubMed Text format Abstract available

PORTACCIO E, Amato MP
Breastfeeding and post-partum relapses in multiple sclerosis patients.
Mult Scler. 2019 Feb 22:1352458519830588. doi: 10.1177/1352458519830588.
PubMed Text format Abstract available

CUKER A, Bass AD, Nadj C, Agius MA, et al
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Mult Scler. 2019 Feb 20:1352458518816612. doi: 10.1177/1352458518816612.
PubMed Text format Abstract available

JAKIMOVSKI D, Ramanathan M, Weinstock-Guttman B, Bergsland N, et al
Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study.
Mult Scler. 2019 Feb 13:1352458519828667. doi: 10.1177/1352458519828667.
PubMed Text format Abstract available

SOTIRCHOS ES, Gonzalez-Caldito N, Dewey BE, Fitzgerald KC, et al
Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.
Mult Scler. 2019 Feb 11:1352458519826364. doi: 10.1177/1352458519826364.
PubMed Text format Abstract available

CICERO CE, Patti F, Lo Fermo S, Giuliano L, et al
Lack of association between Toxocara canis and multiple sclerosis: A population-based case-control study.
Mult Scler. 2019 Feb 11:1352458518825394. doi: 10.1177/1352458518825394.
PubMed Text format

LEFEUVRE JA, Guy JR, Luciano NJ, Ha SK, et al
The spectrum of spinal cord lesions in a primate model of multiple sclerosis.
Mult Scler. 2019 Feb 7:1352458518822408. doi: 10.1177/1352458518822408.
PubMed Text format Abstract available

NICOLETTI CG, Monteleone F, Marfia GA, Usiello A, et al
Oral D-Aspartate enhances synaptic plasticity reserve in progressive multiple sclerosis.
Mult Scler. 2019 Feb 7:1352458519828294. doi: 10.1177/1352458519828294.
PubMed Text format Abstract available

RAIMO S, Spitaleri D, Trojano L, Santangelo G, et al
Apathy as a herald of cognitive changes in multiple sclerosis: A 2-year follow-up study.
Mult Scler. 2019 Feb 7:1352458519828296. doi: 10.1177/1352458519828296.
PubMed Text format Abstract available

PLANCHE V, Su JH, Mournet S, Saranathan M, et al
White-matter-nulled MPRAGE at 7T reveals thalamic lesions and atrophy of specific thalamic nuclei in multiple sclerosis.
Mult Scler. 2019 Feb 7:1352458519828297. doi: 10.1177/1352458519828297.
PubMed Text format Abstract available

January 2019

SECHI E, Flanagan EP
Area postrema syndrome in autoimmune GFAP astrocytopathy.
Mult Scler. 2019 Jan 21:1352458519826489. doi: 10.1177/1352458519826489.
PubMed Text format

STORK L, Bruck W, von Gottberg P, Pulkowski U, et al
Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis.
Mult Scler. 2019 Jan 18:1352458518819098. doi: 10.1177/1352458518819098.
PubMed Text format Abstract available

CORDANI C, Meani A, Esposito F, Valsasina P, et al
Imaging correlates of hand motor performance in multiple sclerosis: A multiparametric structural and functional MRI study.
Mult Scler. 2019 Jan 18:1352458518822145. doi: 10.1177/1352458518822145.
PubMed Text format Abstract available

VALENCIA-SANCHEZ C, Goodman BP, Carter JL, Wingerchuk DM, et al
The spectrum of acute cardiopulmonary events associated with multiple sclerosis exacerbations.
Mult Scler. 2019 Jan 18:1352458518823482. doi: 10.1177/1352458518823482.
PubMed Text format Abstract available

VAN MUNSTER CE, Kaya L, Obura M, Kalkers NF, et al
Minimal clinically important difference of improvement on the Arm Function in Multiple Sclerosis Questionnaire (AMSQ).
Mult Scler. 2019 Jan 18:1352458518823489. doi: 10.1177/1352458518823489.
PubMed Text format Abstract available

MARRODAN M, Alessandro L, Farez MF, Correale J, et al
The role of infections in multiple sclerosis.
Mult Scler. 2019 Jan 14:1352458518823940. doi: 10.1177/1352458518823940.
PubMed Text format Abstract available

PAGANI E, Rocca MA, De Meo E, Horsfield MA, et al
Structural connectivity in multiple sclerosis and modeling of disconnection.
Mult Scler. 2019 Jan 9:1352458518820759. doi: 10.1177/1352458518820759.
PubMed Text format Abstract available

JAKIMOVSKI D, Benedict RH, Marr K, Gandhi S, et al
Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients.
Mult Scler. 2019 Jan 9:1352458518819608. doi: 10.1177/1352458518819608.
PubMed Text format Abstract available

FUCHS TA, Wojcik C, Wilding GE, Pol J, et al
Trait Conscientiousness predicts rate of longitudinal SDMT decline in multiple sclerosis.
Mult Scler. 2019 Jan 7:1352458518820272. doi: 10.1177/1352458518820272.
PubMed Text format Abstract available

December 2018

HOGEL H, Rissanen E, Barro C, Matilainen M, et al
Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
Mult Scler. 2018 Dec 20:1352458518819380. doi: 10.1177/1352458518819380.
PubMed Text format Abstract available

SATCHIDANAND N, Drake A, Smerbeck A, Hojnacki D, et al
Dalfampridine benefits ambulation but not cognition in multiple sclerosis.
Mult Scler. 2018 Dec 19:1352458518815795. doi: 10.1177/1352458518815795.
PubMed Text format Abstract available

ELLIOTT C, Wolinsky JS, Hauser SL, Kappos L, et al
Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.
Mult Scler. 2018 Dec 19:1352458518814117. doi: 10.1177/1352458518814117.
PubMed Text format Abstract available

MATTHEWS L
Clinical commentary on 'Relapsing remitting multiple sclerosis in progressive external ophthalmoplegia: A report of two cases'.
Mult Scler. 2018 Dec 17:1352458518816621. doi: 10.1177/1352458518816621.
PubMed Text format

PATEL KR, Karaa A, Mateen FJ
Relapsing remitting multiple sclerosis in progressive external ophthalmoplegia: A report of two cases.
Mult Scler. 2018 Dec 17:1352458518800794. doi: 10.1177/1352458518800794.
PubMed Text format Abstract available

POURCHER V, Todesco E, Dubois C, Pallier C, et al
False hepatitis B and C viral serologies in patients with multiple sclerosis receiving high-dose biotin.
Mult Scler. 2018 Dec 11:1352458518818294. doi: 10.1177/1352458518818294.
PubMed Text format

BSTEH G, Algrang L, Hegen H, Auer M, et al
Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria.
Mult Scler. 2018 Dec 3:1352458518816614. doi: 10.1177/1352458518816614.
PubMed Text format Abstract available

VAUGHN CB, Kavak KS, Dwyer MG, Bushra A, et al
Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium.
Mult Scler. 2018 Dec 3:1352458518816619. doi: 10.1177/1352458518816619.
PubMed Text format Abstract available

November 2018

CHIEN C, Scheel M, Schmitz-Hubsch T, Borisow N, et al
Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity.
Mult Scler. 2018 Nov 26:1352458518815596. doi: 10.1177/1352458518815596.
PubMed Text format Abstract available

BSTEH G, Berek K, Hegen H, Teuchner B, et al
Smelling multiple sclerosis: Different qualities of olfactory function reflect either inflammatory activity or neurodegeneration.
Mult Scler. 2018 Nov 22:1352458518814113. doi: 10.1177/1352458518814113.
PubMed Text format Abstract available

WOJCIK CM, Rao SM, Schembri AJ, Drake AS, et al
Necessity of technicians for computerized neuropsychological assessment devices in multiple sclerosis.
Mult Scler. 2018 Nov 22:1352458518813287. doi: 10.1177/1352458518813287.
PubMed Text format Abstract available

WALLECZEK NK, Frommlet F, Bsteh G, Eggers C, et al
Month-of-birth-effect in multiple sclerosis in Austria.
Mult Scler. 2018 Nov 22:1352458518810924. doi: 10.1177/1352458518810924.
PubMed Text format Abstract available

SEGAL BM
Enhancing natural killer cells is beneficial in multiple sclerosis - Commentary.
Mult Scler. 2018 Nov 13:1352458518809296. doi: 10.1177/1352458518809296.
PubMed Text format

LIU Q, Shi FD
Enhancing natural killer cells is beneficial in multiple sclerosis - No.
Mult Scler. 2018 Nov 13:1352458518799591. doi: 10.1177/1352458518799591.
PubMed Text format

LARONI A
Enhancing natural killer cells is beneficial in multiple sclerosis - Yes.
Mult Scler. 2018 Nov 13:1352458518800776. doi: 10.1177/1352458518800776.
PubMed Text format

RAATS J, Lamers I, Baert I, Willekens B, et al
Cognitive-motor interference in persons with multiple sclerosis during five upper limb motor tasks with different complexity.
Mult Scler. 2018 Nov 12:1352458518808194. doi: 10.1177/1352458518808194.
PubMed Text format Abstract available

FOX EJ, Markowitz C, Applebee A, Montalban X, et al
Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.
Mult Scler. 2018 Nov 12:1352458518808189. doi: 10.1177/1352458518808189.
PubMed Text format Abstract available

LUIJTEN MA, Eekhout I, D'Hooghe M, Uitdehaag BM, et al
Development of the Arm Function in Multiple Sclerosis Questionnaire-Short Form (AMSQ-SF): A static 10-item version.
Mult Scler. 2018 Nov 9:1352458518808197. doi: 10.1177/1352458518808197.
PubMed Text format Abstract available

LAMERS I, Feys P
Patient reported outcome measures of upper limb function in multiple sclerosis: A critical overview.
Mult Scler. 2018 Nov 9:1352458518809294. doi: 10.1177/1352458518809294.
PubMed Text format

HYUN JW, Kim Y, Kim G, Kim SH, et al
Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis.
Mult Scler. 2018 Nov 7:1352458518810261. doi: 10.1177/1352458518810261.
PubMed Text format Abstract available

ACHIRON A, Sarova-Pinhas I, Magalashvili D, Stern Y, et al
Residual disability after severe relapse in people with multiple sclerosis treated with disease-modifying therapy.
Mult Scler. 2018 Nov 1:1352458518809903. doi: 10.1177/1352458518809903.
PubMed Text format Abstract available

HOBART J, Bowen A, Pepper G, Crofts H, et al
International consensus on quality standards for brain health-focused care in multiple sclerosis.
Mult Scler. 2018 Nov 1:1352458518809326. doi: 10.1177/1352458518809326.
PubMed Text format Abstract available

HEALY BC, Zurawski J, Gonzalez CT, Chitnis T, et al
Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis.
Mult Scler. 2018 Nov 1:1352458518810159. doi: 10.1177/1352458518810159.
PubMed Text format Abstract available

PEETERS LM, van Munster CE, Van Wijmeersch B, Bruyndonckx R, et al
Multidisciplinary data infrastructures in multiple sclerosis: Why they are needed and can be done!
Mult Scler. 2018 Nov 1:1352458518807076. doi: 10.1177/1352458518807076.
PubMed Text format Abstract available

October 2018

FARRELL R
Clinical commentary on "De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine".
Mult Scler. 2018 Oct 30:1352458518810661. doi: 10.1177/1352458518810661.
PubMed Text format

PANICUCCI E, Cohen M, Bourg V, Rocher F, et al
De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine.
Mult Scler. 2018 Oct 30:1352458518790379. doi: 10.1177/1352458518790379.
PubMed Text format Abstract available

DOBSON R
Clinical commentary on 'Life-threatening vitamin D intoxication due to intake of ultra-high doses in multiple sclerosis: a note of caution'.
Mult Scler. 2018 Oct 25:1352458518807053. doi: 10.1177/1352458518807053.
PubMed Text format

FEIGE J, Salmhofer H, Hecker C, Kunz AB, et al
Life-threatening vitamin D intoxication due to intake of ultra-high doses in multiple sclerosis: A note of caution.
Mult Scler. 2018 Oct 25:1352458518807059. doi: 10.1177/1352458518807059.
PubMed Text format Abstract available

AHMAD H, van der Mei I, Taylor BV, Lucas RM, et al
Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis.
Mult Scler. 2018 Oct 23:1352458518806103. doi: 10.1177/1352458518806103.
PubMed Text format Abstract available

SOELBERG SORENSEN P, Giovannoni G, Montalban X, Thalheim C, et al
The Multiple Sclerosis Care Unit.
Mult Scler. 2018 Oct 23:1352458518807082. doi: 10.1177/1352458518807082.
PubMed Text format Abstract available

ROTSTEIN DL, Cortese M, Fung TT, Chitnis T, et al
Diet quality and risk of multiple sclerosis in two cohorts of US women.
Mult Scler. 2018 Oct 23:1352458518807061. doi: 10.1177/1352458518807061.
PubMed Text format Abstract available

STROBER L, DeLuca J, Benedict RH, Jacobs A, et al
Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis.
Mult Scler. 2018 Oct 18:1352458518808204. doi: 10.1177/1352458518808204.
PubMed Text format Abstract available

BURROWS DJ, McGown A, Jain SA, De Felice M, et al
Animal models of multiple sclerosis: From rodents to zebrafish.
Mult Scler. 2018 Oct 15:1352458518805246. doi: 10.1177/1352458518805246.
PubMed Text format Abstract available

DUBUISSON N, Marta M, Gnanapavan S, Turner B, et al
Inclusion criteria used in trials of people with progressive multiple sclerosis.
Mult Scler. 2018 Oct 15:1352458518803769. doi: 10.1177/1352458518803769.
PubMed Text format

GRAF J, Ringelstein M, Lepka K, Schaller J, et al
Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment.
Mult Scler. 2018 Oct 11:1352458518771276. doi: 10.1177/1352458518771276.
PubMed Text format Abstract available

WILLIS MD, Hope-Gill B, Flood-Page P, Joseph F, et al
Sarcoidosis following alemtuzumab treatment for multiple sclerosis.
Mult Scler. 2018 Oct 11:1352458518790391. doi: 10.1177/1352458518790391.
PubMed Text format Abstract available

PFEUFFER S
Sarcoidosis following alemtuzumab treatment: Autoimmunity mediated by T cells and interferon-gamma.
Mult Scler. 2018 Oct 11:1352458518804124. doi: 10.1177/1352458518804124.
PubMed Text format

CONWAY BL, Zeydan B, Uygunoglu U, Novotna M, et al
Age is a critical determinant in recovery from multiple sclerosis relapses.
Mult Scler. 2018 Oct 10:1352458518800815. doi: 10.1177/1352458518800815.
PubMed Text format Abstract available

KALB R, Beier M, Benedict RH, Charvet L, et al
Recommendations for cognitive screening and management in multiple sclerosis care.
Mult Scler. 2018 Oct 10:1352458518803785. doi: 10.1177/1352458518803785.
PubMed Text format Abstract available

VILARINO-GUELL C, Encarnacion M, Bernales CQ, Sadovnick AD, et al
Analysis of Canadian multiple sclerosis patients does not support a role for FKBP6 in disease.
Mult Scler. 2018 Oct 9:1352458518803789. doi: 10.1177/1352458518803789.
PubMed Text format

KREMER D, Akkermann R, Kury P, Dutta R, et al
Current advancements in promoting remyelination in multiple sclerosis.
Mult Scler. 2018 Oct 1:1352458518800827. doi: 10.1177/1352458518800827.
PubMed Text format Abstract available

TATEO F, Grassivaro F, Ermani M, Puthenparampil M, et al
PM2.5 levels strongly associate with multiple sclerosis prevalence in the Province of Padua, Veneto Region, North-East Italy.
Mult Scler. 2018 Oct 1:1352458518803273. doi: 10.1177/1352458518803273.
PubMed Text format Abstract available

September 2018

BOSE G, Atkins HL, Bowman M, Freedman MS, et al
Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis.
Mult Scler. 2018 Sep 25:1352458518802544. doi: 10.1177/1352458518802544.
PubMed Text format Abstract available

MIN M, Spelman T, Lugaresi A, Boz C, et al
Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis.
Mult Scler. 2018 Sep 20:1352458518798147. doi: 10.1177/1352458518798147.
PubMed Text format Abstract available

LAVORGNA L, Brigo F, Moccia M, Leocani L, et al
e-Health and multiple sclerosis: An update.
Mult Scler. 2018 Sep 19:1352458518799629. doi: 10.1177/1352458518799629.
PubMed Text format Abstract available

ANTONAZZO IC, Poluzzi E, Forcesi E, Riise T, et al
Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System.
Mult Scler. 2018 Sep 19:1352458518799598. doi: 10.1177/1352458518799598.
PubMed Text format Abstract available

ROMMER PS, Eichstadt K, Ellenberger D, Flachenecker P, et al
Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry.
Mult Scler. 2018 Sep 19:1352458518799580. doi: 10.1177/1352458518799580.
PubMed Text format Abstract available

O'GRADY KP, Dula AN, Lyttle BD, Thompson LM, et al
Glutamate-sensitive imaging and evaluation of cognitive impairment in multiple sclerosis.
Mult Scler. 2018 Sep 19:1352458518799583. doi: 10.1177/1352458518799583.
PubMed Text format Abstract available

August 2018

VAN ROSSUM JA, Killestein J, Villar LM, Riskind PN, et al
gMS-Classifier1 does not predict disability progression in multiple sclerosis.
Mult Scler. 2018 Aug 31:1352458518798048. doi: 10.1177/1352458518798048.
PubMed Text format

VAN MUNSTER CE, D'Souza M, Steinheimer S, Kamm CP, et al
Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis.
Mult Scler. 2018 Aug 31:1352458518796690. doi: 10.1177/1352458518796690.
PubMed Text format Abstract available

O'MAHONY J, Marrie RA, Laporte A, Bar-Or A, et al
Pediatric-onset multiple sclerosis is associated with reduced parental health-related quality of life and family functioning.
Mult Scler. 2018 Aug 30:1352458518796676. doi: 10.1177/1352458518796676.
PubMed Text format Abstract available

BOVE R, Bevan C, Crabtree E, Zhao C, et al
Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis.
Mult Scler. 2018 Aug 24:1352458518793527. doi: 10.1177/1352458518793527.
PubMed Text format Abstract available

NICHOLAS RS, Han E, Raffel J, Chataway J, et al
Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials.
Mult Scler. 2018 Aug 24:1352458518794063. doi: 10.1177/1352458518794063.
PubMed Text format Abstract available

SKJERBAEK AG, Boesen F, Petersen T, Rasmussen PV, et al
Can we trust self-reported walking distance when determining EDSS scores in patients with multiple sclerosis? The Danish MS hospitals rehabilitation study.
Mult Scler. 2018 Aug 20:1352458518795416. doi: 10.1177/1352458518795416.
PubMed Text format Abstract available

ANDERSEN C, Sondergaard HB, Bang Oturai D, Laursen JH, et al
Alcohol consumption in adolescence is associated with a lower risk of multiple sclerosis in a Danish cohort.
Mult Scler. 2018 Aug 20:1352458518795418. doi: 10.1177/1352458518795418.
PubMed Text format Abstract available

GAUZZI MC
Vitamin D-binding protein and multiple sclerosis: Evidence, controversies, and needs.
Mult Scler. 2018 Aug 16:1352458518792433. doi: 10.1177/1352458518792433.
PubMed Text format Abstract available

SELLEBJERG F, Royen L, Soelberg Sorensen P, Oturai AB, et al
Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
Mult Scler. 2018 Aug 16:1352458518794308. doi: 10.1177/1352458518794308.
PubMed Text format Abstract available

VISWANATHAN S, Wah LM
A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia.
Mult Scler. 2018 Aug 16:1352458518792430. doi: 10.1177/1352458518792430.
PubMed Text format Abstract available

SEEBACHER B, Kuisma R, Glynn A, Berger T, et al
Effects and mechanisms of differently cued and non-cued motor imagery in people with multiple sclerosis: A randomised controlled trial.
Mult Scler. 2018 Aug 14:1352458518795332. doi: 10.1177/1352458518795332.
PubMed Text format Abstract available

PIETROBONI AM, Caprioli M, Carandini T, Scarioni M, et al
CSF beta-amyloid predicts prognosis in patients with multiple sclerosis.
Mult Scler. 2018 Aug 7:1352458518791709. doi: 10.1177/1352458518791709.
PubMed Text format Abstract available

ROCCA MA, Meani A, Fumagalli S, Pagani E, et al
Functional and structural plasticity following action observation training in multiple sclerosis.
Mult Scler. 2018 Aug 7:1352458518792771. doi: 10.1177/1352458518792771.
PubMed Text format Abstract available

KUSPINAR A, Mayo NE
Validation of the preference-based multiple sclerosis index.
Mult Scler. 2018 Aug 2:1352458518792423. doi: 10.1177/1352458518792423.
PubMed Text format Abstract available

TOMASSINI V, Fanelli F, Prosperini L, Cerqua R, et al
Predicting the profile of increasing disability in multiple sclerosis.
Mult Scler. 2018 Aug 2:1352458518790397. doi: 10.1177/1352458518790397.
PubMed Text format Abstract available

PETERSEN ER, Sondergaard HB, Laursen JH, Olsson AG, et al
Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis.
Mult Scler. 2018 Aug 2:1352458518791753. doi: 10.1177/1352458518791753.
PubMed Text format Abstract available

DI STADIO A, Ralli M
Inner ear involvement in multiple sclerosis: An underestimated condition?
Mult Scler. 2018;24:1264-1265.
PubMed Text format

BHAN A, Jacobsen C, Myhr KM, Dalen I, et al
Neurofilaments and 10-year follow-up in multiple sclerosis.
Mult Scler. 2018 Aug 1:1352458518782005. doi: 10.1177/1352458518782005.
PubMed Text format Abstract available

July 2018

YANG R, Dunn JF
Multiple sclerosis disease progression: Contributions from a hypoxia-inflammation cycle.
Mult Scler. 2018 Jul 27:1352458518791683. doi: 10.1177/1352458518791683.
PubMed Text format Abstract available

SACCA F, Lanzillo R, Signori A, Maniscalco GT, et al
Determinants of therapy switch in multiple sclerosis treatment-naive patients: A real-life study.
Mult Scler. 2018 Jul 25:1352458518790390. doi: 10.1177/1352458518790390.
PubMed Text format Abstract available

HYUN JW, Kim W, Huh SY, Park MS, et al
Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome.
Mult Scler. 2018 Jul 25:1352458518790702. doi: 10.1177/1352458518790702.
PubMed Text format Abstract available

HOLM HANSEN R, Hojsgaard Chow H, Sellebjerg F, Rode von Essen M, et al
Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis.
Mult Scler. 2018 Jul 25:1352458518790417. doi: 10.1177/1352458518790417.
PubMed Text format Abstract available

COHEN JA, Comi G, Arnold DL, Bar-Or A, et al
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
Mult Scler. 2018 Jul 25:1352458518789884. doi: 10.1177/1352458518789884.
PubMed Text format Abstract available

LIN F, Zivadinov R, Hagemeier J, Weinstock-Guttman B, et al
Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition.
Mult Scler. 2018 Jul 1:1352458518788218. doi: 10.1177/1352458518788218.
PubMed Text format Abstract available

SENDERS A, Hanes D, Bourdette D, Carson K, et al
Impact of mindfulness-based stress reduction for people with multiple sclerosis at 8 weeks and 12 months: A randomized clinical trial.
Mult Scler. 2018 Jul 1:1352458518786650. doi: 10.1177/1352458518786650.
PubMed Text format Abstract available

FISSOLO N, Cervera-Carles L, Villar Guimerans LM, Lleo A, et al
Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis.
Mult Scler. 2018 Jul 1:1352458518786055. doi: 10.1177/1352458518786055.
PubMed Text format Abstract available

OSHIMA Y, Tanimoto T, Yuji K, Tojo A, et al
Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
Mult Scler. 2018 Jul 1:1352458518786075. doi: 10.1177/1352458518786075.
PubMed Text format Abstract available

WIJNANDS JM, Zhu F, Kingwell E, Zhao Y, et al
Five years before multiple sclerosis onset: Phenotyping the prodrome.
Mult Scler. 2018 Jul 1:1352458518783662. doi: 10.1177/1352458518783662.
PubMed Text format Abstract available

WONG YYM, van der Vuurst de Vries RM, van Pelt ED, Ketelslegers IA, et al
T-cell activation marker sCD27 is associated with clinically definite multiple sclerosis in childhood-acquired demyelinating syndromes.
Mult Scler. 2018 Jul 1:1352458518786655. doi: 10.1177/1352458518786655.
PubMed Text format Abstract available

KEARNEY H
Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - No.
Mult Scler. 2018 Jul 1:1352458518770279. doi: 10.1177/1352458518770279.
PubMed Text format

SASTRE-GARRIGA J
Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - Commentary.
Mult Scler. 2018 Jul 1:1352458518783362. doi: 10.1177/1352458518783362.
PubMed Text format

CORTESE R, Ciccarelli O
Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - Yes.
Mult Scler. 2018 Jul 1:1352458518778010. doi: 10.1177/1352458518778010.
PubMed Text format

June 2018

MESCHERIAKOVA JY, Verkerk AJ, Amin N, Uitterlinden AG, et al
Linkage analysis and whole exome sequencing identify a novel candidate gene in a Dutch multiple sclerosis family.
Mult Scler. 2018 Jun 1:1352458518777202. doi: 10.1177/1352458518777202.
PubMed Text format Abstract available

PUTHENPARAMPIL M, Zito A, Pantano G, Federle L, et al
Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset.
Mult Scler. 2018 Jun 1:1352458518779951. doi: 10.1177/1352458518779951.
PubMed Text format Abstract available

AL HUSSONA M, Kearney H, Fisher A, Lynch J, et al
New onset seizures as a sole clinical presentation of multiple sclerosis.
Mult Scler. 2018 Jun 1:1352458518781994. doi: 10.1177/1352458518781994.
PubMed Text format Abstract available

REDDEL SW, Barnett MH, Riminton S, Dugal T, et al
Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study.
Mult Scler. 2018 Jun 1:1352458518783673. doi: 10.1177/1352458518783673.
PubMed Text format Abstract available

CHEN J, Taylor B, Palmer AJ, Kirk-Brown A, et al
Estimating MS-related work productivity loss and factors associated with work productivity loss in a representative Australian sample of people with multiple sclerosis.
Mult Scler. 2018 Jun 1:1352458518781971. doi: 10.1177/1352458518781971.
PubMed Text format Abstract available

MANOUCHEHRINIA A, Zhu F, Piani-Meier D, Lange M, et al
Predicting risk of secondary progression in multiple sclerosis: A nomogram.
Mult Scler. 2018 Jun 1:1352458518783667. doi: 10.1177/1352458518783667.
PubMed Text format Abstract available

GALLAGHER LG, Ilango S, Wundes A, Stobbe GA, et al
Lifetime exposure to ultraviolet radiation and the risk of multiple sclerosis in the US radiologic technologists cohort study.
Mult Scler. 2018 Jun 1:1352458518783343. doi: 10.1177/1352458518783343.
PubMed Text format Abstract available

MAGALHAES S, Banwell B, Bar-Or A, Fortier I, et al
A framework for measurement and harmonization of pediatric multiple sclerosis etiologic research studies: The Pediatric MS Tool-Kit.
Mult Scler. 2018 Jun 1:1352458518783345. doi: 10.1177/1352458518783345.
PubMed Text format Abstract available

ALVES-LEON SV, Lima MDR, Nunes PCG, Chimelli LMC, et al
Zika virus found in brain tissue of a multiple sclerosis patient undergoing an acute disseminated encephalomyelitis-like episode.
Mult Scler. 2018 Jun 1:1352458518781992. doi: 10.1177/1352458518781992.
PubMed Text format Abstract available

May 2018

FROEHLICH A, Schmidt S, Landsberg J, Bieber T, et al
Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod.
Mult Scler. 2018 May 1:1352458518774444. doi: 10.1177/1352458518774444.
PubMed Text format

NAUTA IM, Balk LJ, Sonder JM, Hulst HE, et al
The clinical value of the patient-reported multiple sclerosis neuropsychological screening questionnaire.
Mult Scler. 2018 May 1:1352458518777295. doi: 10.1177/1352458518777295.
PubMed Text format Abstract available

ROMME CHRISTENSEN J, Komori M, von Essen MR, Ratzer R, et al
CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.
Mult Scler. 2018 May 1:1352458518774880. doi: 10.1177/1352458518774880.
PubMed Text format Abstract available

MILLS EA, Mao-Draayer Y
Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients.
Mult Scler. 2018 May 1:1352458518775550. doi: 10.1177/1352458518775550.
PubMed Text format Abstract available

VAN DER VUURST DE VRIES RM, Wong YYM, Mescheriakova JY, van Pelt ED, et al
High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome.
Mult Scler. 2018 May 1:1352458518775303. doi: 10.1177/1352458518775303.
PubMed Text format Abstract available

SCHEE JP, Viswanathan S
Pure spinal multiple sclerosis: A possible novel entity within the multiple sclerosis disease spectrum.
Mult Scler. 2018 May 1:1352458518775912. doi: 10.1177/1352458518775912.
PubMed Text format Abstract available

BOESEN MS, Koch-Henriksen N, Thygesen LC, Eriksson F, et al
Infections seem to be more frequent before onset of pediatric multiple sclerosis: A Danish nationwide nested case-control study.
Mult Scler. 2018 May 1:1352458518771871. doi: 10.1177/1352458518771871.
PubMed Text format Abstract available

BAKER G, Nair KPS, Baster K, Rosato R, et al
Reliability and acceptability of the Multiple Sclerosis Quality of Life-29 questionnaire in an English-speaking cohort.
Mult Scler. 2018 May 1:1352458518776583. doi: 10.1177/1352458518776583.
PubMed Text format Abstract available

BEESLEY R, Anderson V, Harding KE, Joseph F, et al
Impact of the 2017 revisions to McDonald criteria on the diagnosis of multiple sclerosis.
Mult Scler. 2018 May 1:1352458518778007. doi: 10.1177/1352458518778007.
PubMed Text format

HUGOS CL, Cameron MH, Chen Z, Chen Y, et al
A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Long-term (12-month) follow-up at one site.
Mult Scler. 2018 May 1:1352458518775920. doi: 10.1177/1352458518775920.
PubMed Text format Abstract available

TSAGKAS C, Magon S, Gaetano L, Pezold S, et al
Preferential spinal cord volume loss in primary progressive multiple sclerosis.
Mult Scler. 2018 May 1:1352458518775006. doi: 10.1177/1352458518775006.
PubMed Text format Abstract available

MARANZANO J, Till C, Assemlal HE, Fonov V, et al
Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI.
Mult Scler. 2018 May 1:1352458518779952. doi: 10.1177/1352458518779952.
PubMed Text format Abstract available

BJORNEVIK K, Myhr KM, Beiske A, Bjerve KS, et al
alpha-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients.
Mult Scler. 2018 May 1:1352458518779925. doi: 10.1177/1352458518779925.
PubMed Text format Abstract available

April 2018

ALMEIDA KJ, Barreto-Soares RV, Campos-Sousa RN, Campos-Sousa MG, et al
Pulmonary paracoccidioidomycosis associated with the use of natalizumab in multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518763091. doi: 10.1177/1352458518763091.
PubMed Text format Abstract available

MCNICHOLAS N, Lockhart A, Yap SM, O'Connell K, et al
New versus old: Implications of evolving diagnostic criteria for relapsing-remitting multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518770088. doi: 10.1177/1352458518770088.
PubMed Text format Abstract available

KREMER D, Kury P, Hartung HP
ECTRIMS/ACTRIMS 2017: Closing in on neurorepair in progressive multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518768770. doi: 10.1177/1352458518768770.
PubMed Text format Abstract available

KOBELT G, Langdon D, Jonsson L
The effect of self-assessed fatigue and subjective cognitive impairment on work capacity: The case of multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518769837. doi: 10.1177/1352458518769837.
PubMed Text format Abstract available

VAVASOUR IM, Tam R, Li DK, Laule C, et al
A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab.
Mult Scler. 2018 Apr 1:1352458518770085. doi: 10.1177/1352458518770085.
PubMed Text format Abstract available

MARRIE RA, Montalban X
Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night.
Mult Scler. 2018;24:558-562.
PubMed Text format

LORSCHEIDER J, Benkert P, Lienert C, Hanni P, et al
Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518768433. doi: 10.1177/1352458518768433.
PubMed Text format Abstract available

SAUL A, Taylor B, Simpson S Jr, Ponsonby AL, et al
Polymorphism in the serotonin transporter gene polymorphisms ( 5-HTTLPR) modifies the association between significant life events and depression in people with multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518770021. doi: 10.1177/1352458518770021.
PubMed Text format Abstract available

LLUFRIU S, Rocca MA, Pagani E, Riccitelli GC, et al
Hippocampal-related memory network in multiple sclerosis: A structural connectivity analysis.
Mult Scler. 2018 Apr 1:1352458518771838. doi: 10.1177/1352458518771838.
PubMed Text format Abstract available

CREARY LE, Mallempati KC, Gangavarapu S, Caillier SJ, et al
Deconstruction of HLA-DRB1*04:01:01 and HLA-DRB1*15:01:01 class II haplotypes using next-generation sequencing in European-Americans with multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518770019. doi: 10.1177/1352458518770019.
PubMed Text format Abstract available

MCCLURG D, Bugge C, Elders A, Irshad T, et al
Factors affecting continuation of clean intermittent catheterisation in people with multiple sclerosis: Results of the COSMOS mixed-methods study.
Mult Scler. 2018 Apr 1:1352458518768722. doi: 10.1177/1352458518768722.
PubMed Text format Abstract available

WAGLEY S, Bokori-Brown M, Morcrette H, Malaspina A, et al
Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518767327. doi: 10.1177/1352458518767327.
PubMed Text format Abstract available

GIOVANNONI G, Soelberg Sorensen P, Cook S, Rammohan KW, et al
Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
Mult Scler. 2018 Apr 1:1352458518771875. doi: 10.1177/1352458518771875.
PubMed Text format Abstract available

GIORDANA MT, Cavalla P, Uccelli A, Laroni A, et al
Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation.
Mult Scler. 2018 Apr 1:1352458518763095. doi: 10.1177/1352458518763095.
PubMed Text format Abstract available

GIACOMINI PS
Rebound disease in multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518772913. doi: 10.1177/1352458518772913.
PubMed Text format

HARMEL P, Schlunk F, Harms L
Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report.
Mult Scler. 2018 Apr 1:1352458517741191. doi: 10.1177/1352458517741191.
PubMed Text format Abstract available

March 2018

KOENIG KA, Rao SM, Lowe MJ, Lin J, et al
The role of the thalamus and hippocampus in episodic memory performance in patients with multiple sclerosis.
Mult Scler. 2018 Mar 1:1352458518760716. doi: 10.1177/1352458518760716.
PubMed Text format Abstract available

GOBEL K, Ruck T, Meuth SG
Cytokine signaling in multiple sclerosis: Lost in translation.
Mult Scler. 2018 Mar 1:1352458518763094. doi: 10.1177/1352458518763094.
PubMed Text format Abstract available

LEE JY, De Jager PL
What is the epigenome and is it involved in multiple sclerosis?
Mult Scler. 2018;24:268-269.
PubMed Text format

SILLER N, Kuhle J, Muthuraman M, Barro C, et al
Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
Mult Scler. 2018 Mar 1:1352458518765666. doi: 10.1177/1352458518765666.
PubMed Text format Abstract available

SOWA P, Harbo HF, White NS, Celius EG, et al
Restriction spectrum imaging of white matter and its relation to neurological disability in multiple sclerosis.
Mult Scler. 2018 Mar 1:1352458518765671. doi: 10.1177/1352458518765671.
PubMed Text format Abstract available

CORTI L, Ayrignac X, Carra Dalliere C, Charif M, et al
Late activity rebound in non-active multiple sclerosis: A rare event.
Mult Scler. 2018 Mar 1:1352458518765670. doi: 10.1177/1352458518765670.
PubMed Text format

CASTELLI L, Prosperini L, Pozzilli C
Balance worsening associated with nabiximols in multiple sclerosis.
Mult Scler. 2018 Mar 1:1352458518765649. doi: 10.1177/1352458518765649.
PubMed Text format Abstract available

GRAETZ C, Groger A, Luessi F, Salmen A, et al
Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.
Mult Scler. 2018 Mar 1:1352458518763541. doi: 10.1177/1352458518763541.
PubMed Text format Abstract available

HUA LH, Fan TH, Conway D, Thompson N, et al
Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60.
Mult Scler. 2018 Mar 1:1352458518765656. doi: 10.1177/1352458518765656.
PubMed Text format Abstract available

LANZILLO R, Moccia M, Criscuolo C, Cennamo G, et al
Optical coherence tomography angiography detects retinal vascular alterations in different phases of multiple sclerosis.
Mult Scler. 2018 Mar 1:1352458518768060. doi: 10.1177/1352458518768060.
PubMed Text format

VAN GEEST Q, Boeschoten RE, Keijzer MJ, Steenwijk MD, et al
Fronto-limbic disconnection in patients with multiple sclerosis and depression.
Mult Scler. 2018 Mar 1:1352458518767051. doi: 10.1177/1352458518767051.
PubMed Text format Abstract available

TOLEDANO M, Weinshenker BG, Kaufmann TJ, Parisi JE, et al
Demographics and clinical characteristics of episodic hypothermia in multiple sclerosis.
Mult Scler. 2018 Mar 1:1352458518767045. doi: 10.1177/1352458518767045.
PubMed Text format Abstract available

LEIBOVITCH EC, Lin CM, Billioux BJ, Graves J, et al
Prevalence of salivary human herpesviruses in pediatric multiple sclerosis cases and controls.
Mult Scler. 2018 Mar 1:1352458518765654. doi: 10.1177/1352458518765654.
PubMed Text format Abstract available

KIRA JI
Reply to letter to the editor: Dimethyl fumarate for patients with neuromyelitis optica spectrum disorder by Pitarokoili and Gold.
Mult Scler. 2018;24:366-367.
PubMed Text format

YAMOUT BI, Zeineddine MM
Letter to the editor.
Mult Scler. 2018;24:363.
PubMed Text format

PITAROKOILI K, Gold R
Dimethyl fumarate for patients with neuromyelitis optica spectrum disorder.
Mult Scler. 2018;24:364-365.
PubMed Text format

February 2018

JAEGER S, Paul F, Scheel M, Brandt A, et al
Multiple sclerosis-related fatigue: Altered resting-state functional connectivity of the ventral striatum and dorsolateral prefrontal cortex.
Mult Scler. 2018 Feb 1:1352458518758911. doi: 10.1177/1352458518758911.
PubMed Text format Abstract available

DE STEFANO N, Giorgio A, Tintore M, Pia Amato M, et al
Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations.
Mult Scler. 2018;24:214-221.
PubMed Text format

ROOSTAEI T, Sadaghiani S, Mashhadi R, Falahatian M, et al
Convergent effects of a functional C3 variant on brain atrophy, demyelination, and cognitive impairment in multiple sclerosis.
Mult Scler. 2018 Feb 1:1352458518760715. doi: 10.1177/1352458518760715.
PubMed Text format Abstract available

CAVALERA C, Rovaris M, Mendozzi L, Pugnetti L, et al
Online meditation training for people with multiple sclerosis: A randomized controlled trial.
Mult Scler. 2018 Feb 1:1352458518761187. doi: 10.1177/1352458518761187.
PubMed Text format Abstract available

CAMARA-LEMARROY CR, Castillo J, Sastre-Garriga J, Tintore M, et al
Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report.
Mult Scler. 2018 Feb 1:1352458518761185. doi: 10.1177/1352458518761185.
PubMed Text format Abstract available

PIEHL F, Hillert J
Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Yes.
Mult Scler. 2018 Feb 1:1352458518757930. doi: 10.1177/1352458518757930.
PubMed Text format

CREE BA
Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Commentary.
Mult Scler. 2018 Feb 1:1352458518760717. doi: 10.1177/1352458518760717.
PubMed Text format

WALLIN MT
Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - No.
Mult Scler. 2018 Feb 1:1352458518757931. doi: 10.1177/1352458518757931.
PubMed Text format

BARKHOF F
The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing MS - Commentary.
Mult Scler. 2018;24:125-126.
PubMed Text format

PORTER B
Commentary on "Localized pigmentation disorder after subcutaneous pegylated interferon beta 1a injection" by Coghe et al.
Mult Scler. 2018;24:233-235.
PubMed Text format

January 2018

HILVEN K, Vandebergh M, Smets I, Mallants K, et al
Genetic basis for relapse rate in multiple sclerosis: Association with LRP2 genetic variation.
Mult Scler. 2018 Jan 1:1352458517749894. doi: 10.1177/1352458517749894.
PubMed Text format Abstract available

FEUCHT N, Maier M, Lepennetier G, Pettenkofer M, et al
Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458517750009. doi: 10.1177/1352458517750009.
PubMed Text format Abstract available

DI STADIO A, Ralli M
Inner ear involvement in multiple sclerosis: An underestimated condition?
Mult Scler. 2018 Jan 1:1352458518750010. doi: 10.1177/1352458518750010.
PubMed Text format

DAMOTTE V, Lizee A, Tremblay M, Agrawal A, et al
Harnessing electronic medical records to advance research on multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458517747407. doi: 10.1177/1352458517747407.
PubMed Text format Abstract available

DE STEFANO N, Giorgio A
Response to 'Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?' by Schiffmann et al.
Mult Scler. 2018 Jan 1:1352458517748476. doi: 10.1177/1352458517748476.
PubMed Text format

SCHIFFMANN I, Scheiderbauer J, Riemann-Lorenz K, Heesen C, et al
Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?
Mult Scler. 2018 Jan 1:1352458517749895. doi: 10.1177/1352458517749895.
PubMed Text format

SEGAL BM, Cohen JA, Antel J
Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2017: Environmental factors, genetics, and epigenetics in MS susceptibility and clinical course.
Mult Scler. 2018;24:4-5.
PubMed Text format Abstract available

TREMLETT H, Waubant E
Gut microbiome and pediatric multiple sclerosis.
Mult Scler. 2018;24:64-68.
PubMed Text format Abstract available

CASTRO K, Casaccia P
Epigenetic modifications in brain and immune cells of multiple sclerosis patients.
Mult Scler. 2018;24:69-74.
PubMed Text format Abstract available

TANKOU SK, Regev K, Healy BC, Cox LM, et al
Investigation of probiotics in multiple sclerosis.
Mult Scler. 2018;24:58-63.
PubMed Text format Abstract available

VOSKUHL RR, Sawalha AH, Itoh Y
Sex chromosome contributions to sex differences in multiple sclerosis susceptibility and progression.
Mult Scler. 2018;24:22-31.
PubMed Text format Abstract available

HAASE S, Haghikia A, Gold R, Linker RA, et al
Dietary fatty acids and susceptibility to multiple sclerosis.
Mult Scler. 2018;24:12-16.
PubMed Text format Abstract available

HARROUD A, Richards JB
Mendelian randomization in multiple sclerosis: A causal role for vitamin D and obesity?
Mult Scler. 2018;24:80-85.
PubMed Text format Abstract available

DOLEI A
The aliens inside us: HERV-W endogenous retroviruses and multiple sclerosis.
Mult Scler. 2018;24:42-47.
PubMed Text format Abstract available

CANTO E, Oksenberg JR
Multiple sclerosis genetics.
Mult Scler. 2018;24:75-79.
PubMed Text format Abstract available

WAUBANT E
Effect of puberty on multiple sclerosis risk and course.
Mult Scler. 2018;24:32-35.
PubMed Text format Abstract available

HODEL J, Bapst B, Outteryck O, Verclytte S, et al
Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
Mult Scler. 2018 Jan 1:1352458517750765. doi: 10.1177/1352458517750765.
PubMed Text format Abstract available

BOVE R, Healy BC, Musallam A, Soltany P, et al
Fatty acid binding protein-4 is associated with disability in multiple sclerosis patients.
Mult Scler. 2018 Jan 1:1352458517750768. doi: 10.1177/1352458517750768.
PubMed Text format Abstract available

RIMKUS CM, Schoonheim MM, Steenwijk MD, Vrenken H, et al
Gray matter networks and cognitive impairment in multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458517751650. doi: 10.1177/1352458517751650.
PubMed Text format Abstract available

COHEN JA, Hunter SF, Brown TR, Gudesblatt M, et al
Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
Mult Scler. 2018 Jan 1:1352458518754716. doi: 10.1177/1352458518754716.
PubMed Text format Abstract available

BARONCINI D, Zaffaroni M, Moiola L, Lorefice L, et al
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study.
Mult Scler. 2018 Jan 1:1352458518754364. doi: 10.1177/1352458518754364.
PubMed Text format Abstract available

FORD HL, Wicks CR, Stroud A, Tennant A, et al
Psychological determinants of job retention in multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458518754362. doi: 10.1177/1352458518754362.
PubMed Text format Abstract available

ROY S, Drake A, Fuchs T, Dwyer MG, et al
Longitudinal personality change associated with cognitive decline in multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458517753720. doi: 10.1177/1352458517753720.
PubMed Text format Abstract available

HAUPTS MR, Spill-Askeridis P, Humpert M, Seidel D, et al
Acute exacerbations after decades of non-active chronic multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458518754365. doi: 10.1177/1352458518754365.
PubMed Text format

DI IOIA M, Farina D, di Tommaso V, Travaglini D, et al
Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458517743093. doi: 10.1177/1352458517743093.
PubMed Text format Abstract available

MEUNIER B, Rico A, Seguier J, Boutiere C, et al
Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
Mult Scler. 2018 Jan 1:1352458517729766. doi: 10.1177/1352458517729766.
PubMed Text format Abstract available

MONTALBAN X, Gold R, Thompson AJ, Otero-Romero S, et al
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458517751049. doi: 10.1177/1352458517751049.
PubMed Text format Abstract available

LAVERY AM, Collins BN, Waldman AT, Hart CN, et al
The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk.
Mult Scler. 2018 Jan 1:1352458518757089. doi: 10.1177/1352458518757089.
PubMed Text format Abstract available

December 2017

KROTH J, Ciolac D, Fleischer V, Koirala N, et al
Increased cerebrospinal fluid albumin and immunoglobulin A fractions forecast cortical atrophy and longitudinal functional deterioration in relapsing-remitting multiple sclerosis.
Mult Scler. 2017 Dec 1:1352458517748474. doi: 10.1177/1352458517748474.
PubMed Text format Abstract available

HUGOS CL, Chen Z, Chen Y, Turner AP, et al
A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Short- and medium-term benefits.
Mult Scler. 2017 Dec 1:1352458517745723. doi: 10.1177/1352458517745723.
PubMed Text format Abstract available

CALLESEN J, Richter C, Kristensen C, Sunesen I, et al
Test-retest agreement and reliability of the Six Spot Step Test in persons with multiple sclerosis.
Mult Scler. 2017 Dec 1:1352458517745725. doi: 10.1177/1352458517745725.
PubMed Text format Abstract available

PEETERS LM
Fair data for next-generation management of multiple sclerosis.
Mult Scler. 2017 Dec 1:1352458517748475. doi: 10.1177/1352458517748475.
PubMed Text format Abstract available

November 2017

GRAN-RUAZ S, Mani A, O'Quinn S
An overview of biosimilars and non-biologic complex drugs in Europe, the United States, and Canada and their relevance to multiple sclerosis.
Mult Scler. 2017 Nov 1:1352458517739976. doi: 10.1177/1352458517739976.
PubMed Text format Abstract available

MANCARDI G, Sormani MP, Muraro PA, Boffa G, et al
Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis.
Mult Scler. 2017 Nov 1:1352458517742532. doi: 10.1177/1352458517742532.
PubMed Text format Abstract available

PIETROBONI AM, Dell'Arti L, Caprioli M, Scarioni M, et al
The loss of macular ganglion cells begins from the early stages of disease and correlates with brain atrophy in multiple sclerosis patients.
Mult Scler. 2017 Nov 1:1352458517740214. doi: 10.1177/1352458517740214.
PubMed Text format Abstract available

MALHOTRA S, Sorosina M, Rio J, Peroni S, et al
NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients.
Mult Scler. 2017 Nov 1:1352458517739137. doi: 10.1177/1352458517739137.
PubMed Text format Abstract available

MALINOVA TS, Dijkstra CD, de Vries HE
Serotonin: A mediator of the gut-brain axis in multiple sclerosis.
Mult Scler. 2017 Nov 1:1352458517739975. doi: 10.1177/1352458517739975.
PubMed Text format Abstract available

ABBOUD H, Hill E, Siddiqui J, Serra A, et al
Neuromodulation in multiple sclerosis.
Mult Scler. 2017;23:1663-1676.
PubMed Text format Abstract available

FEYS P, Moumdjian L, Van Halewyck F, Wens I, et al
Effects of an individual 12-week community-located "start-to-run" program on physical capacity, walking, fatigue, cognitive function, brain volumes, and structures in persons with multiple sclerosis.
Mult Scler. 2017 Nov 1:1352458517740211. doi: 10.1177/1352458517740211.
PubMed Text format Abstract available

LOREFICE L, Fenu G, Sardu C, Frau J, et al
Multiple sclerosis and HLA genotypes: A possible influence on brain atrophy.
Mult Scler. 2017 Nov 1:1352458517739989. doi: 10.1177/1352458517739989.
PubMed Text format Abstract available

WINGES KM, Murchison CF, Bourdette DN, Spain RI, et al
Longitudinal optical coherence tomography study of optic atrophy in secondary progressive multiple sclerosis: Results from a clinical trial cohort.
Mult Scler. 2017 Nov 1:1352458517739136. doi: 10.1177/1352458517739136.
PubMed Text format Abstract available

UHER T, Vaneckova M, Krasensky J, Sobisek L, et al
Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.
Mult Scler. 2017 Nov 1:1352458517742739. doi: 10.1177/1352458517742739.
PubMed Text format Abstract available

KAVALIUNAS A, Danylaite Karrenbauer V, Gyllensten H, Manouchehrinia A, et al
Cognitive function is a major determinant of income among multiple sclerosis patients in Sweden acting independently from physical disability.
Mult Scler. 2017 Nov 1:1352458517740212. doi: 10.1177/1352458517740212.
PubMed Text format Abstract available

AGIUS MA, Klodowska-Duda G, Maciejowski M, Potemkowski A, et al
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.
Mult Scler. 2017 Nov 1:1352458517740641. doi: 10.1177/1352458517740641.
PubMed Text format Abstract available

SPITERI S, Hassa T, Claros-Salinas D, Dettmers C, et al
Neural correlates of effort-dependent and effort-independent cognitive fatigue components in patients with multiple sclerosis.
Mult Scler. 2017 Nov 1:1352458517743090. doi: 10.1177/1352458517743090.
PubMed Text format Abstract available

RICCITELLI GC, Pagani E, Rodegher M, Colombo B, et al
Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis.
Mult Scler. 2017 Nov 1:1352458517743091. doi: 10.1177/1352458517743091.
PubMed Text format Abstract available

October 2017

MOSS-MORRIS R, Norton S
Aerobic exercise, cognitive behavioural therapy and energy conservation management for multiple sclerosis (MS) fatigue: Are three trials better than one?
Mult Scler. 2017;23:1436-1440.
PubMed Text format

ZETTERBERG H, Teunissen C
Fluid biomarkers for disease activity in multiple sclerosis.
Mult Scler. 2017 Oct 1:1352458517736151. doi: 10.1177/1352458517736151.
PubMed Text format

BOESEN F, Norgaard M, Trenel P, Rasmussen PV, et al
Longer term effectiveness of inpatient multidisciplinary rehabilitation on health-related quality of life in MS patients: a pragmatic randomized controlled trial - The Danish MS Hospitals Rehabilitation Study.
Mult Scler. 2017 Oct 1:1352458517735188. doi: 10.1177/1352458517735188.
PubMed Text format Abstract available

GIANFRANCESCO MA, Stridh P, Shao X, Rhead B, et al
Genetic risk factors for pediatric-onset multiple sclerosis.
Mult Scler. 2017 Oct 1:1352458517733551. doi: 10.1177/1352458517733551.
PubMed Text format Abstract available

VAN KEMPEN ZL, Rispens T, Killestein J
Response to "Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".
Mult Scler. 2017 Oct 1:1352458517734073. doi: 10.1177/1352458517734073.
PubMed Text format

FOX RJ, Chataway J
Advancing trial design in progressive multiple sclerosis.
Mult Scler. 2017;23:1573-1578.
PubMed Text format Abstract available

MILLER DH, Thompson AJ
Advancing trial design in progressive multiple sclerosis.
Mult Scler. 2017;23:1571-1572.
PubMed Text format

MOCCIA M, de Stefano N, Barkhof F
Imaging outcome measures for progressive multiple sclerosis trials.
Mult Scler. 2017;23:1614-1626.
PubMed Text format Abstract available

PICHLER A, Khalil M, Langkammer C, Pinter D, et al
The impact of vascular risk factors on brain volume and lesion load in patients with early multiple sclerosis.
Mult Scler. 2017 Oct 1:1352458517736149. doi: 10.1177/1352458517736149.
PubMed Text format Abstract available

GLAZER CH, Tottenborg SS, Giwercman A, Brauner EV, et al
Male factor infertility and risk of multiple sclerosis: A register-based cohort study.
Mult Scler. 2017 Oct 1:1352458517734069. doi: 10.1177/1352458517734069.
PubMed Text format Abstract available

TINELLI M, Kanavos P, Efthymiadou O, Visintin E, et al
Using IMPrESS to guide policy change in multiple sclerosis.
Mult Scler. 2017 Oct 1:1352458517737388. doi: 10.1177/1352458517737388.
PubMed Text format Abstract available

DONADIEU M, Le Fur Y, Maarouf A, Gherib S, et al
Metabolic counterparts of sodium accumulation in multiple sclerosis: A whole brain 23Na-MRI and fast 1H-MRSI study.
Mult Scler. 2017 Oct 1:1352458517736146. doi: 10.1177/1352458517736146.
PubMed Text format Abstract available

FLEMING J, Hernandez G, Hartman L, Maksimovic J, et al
Safety and efficacy of helminth treatment in relapsing-remitting multiple sclerosis: Results of the HINT 2 clinical trial.
Mult Scler. 2017 Oct 1:1352458517736377. doi: 10.1177/1352458517736377.
PubMed Text format Abstract available

BSTEH G, Hegen H, Teuchner B, Amprosi M, et al
Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis.
Mult Scler. 2017 Oct 1:1352458517740216. doi: 10.1177/1352458517740216.
PubMed Text format Abstract available

LEAVITT VM, Blanchard AR, Guo CY, Gelernt E, et al
Aspirin is an effective pretreatment for exercise in multiple sclerosis: A double-blind randomized controlled pilot trial.
Mult Scler. 2017 Oct 1:1352458517739138. doi: 10.1177/1352458517739138.
PubMed Text format Abstract available

DEKKER I, Sombekke MH, Witte BI, Geurts JJ, et al
Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis.
Mult Scler. 2017 Oct 1:1352458517736147. doi: 10.1177/1352458517736147.
PubMed Text format Abstract available

September 2017

TOBYNE SM, Ochoa WB, Bireley JD, Smith VM, et al
Cognitive impairment and the regional distribution of cerebellar lesions in multiple sclerosis.
Mult Scler. 2017 Sep 1:1352458517730132. doi: 10.1177/1352458517730132.
PubMed Text format Abstract available

FAZIA T, Pastorino R, Foco L, Han L, et al
Investigating multiple sclerosis genetic susceptibility on the founder population of east-central Sardinia via association and linkage analysis of immune-related loci.
Mult Scler. 2017 Sep 1:1352458517732841. doi: 10.1177/1352458517732841.
PubMed Text format Abstract available

HUPPKE P, Huppke B, Ellenberger D, Rostasy K, et al
Therapy of highly active pediatric multiple sclerosis.
Mult Scler. 2017 Sep 1:1352458517732843. doi: 10.1177/1352458517732843.
PubMed Text format Abstract available

LANZILLO R, Cennamo G, Criscuolo C, Carotenuto A, et al
Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis.
Mult Scler. 2017 Sep 1:1352458517729463. doi: 10.1177/1352458517729463.
PubMed Text format Abstract available

COMBER L, Quinn G, McGuigan C, Galvin R, et al
Medication usage and falls in people with multiple sclerosis.
Mult Scler. 2017 Sep 1:1352458517731912. doi: 10.1177/1352458517731912.
PubMed Text format Abstract available

MEINL I, Havla J, Hohlfeld R, Kumpfel T, et al
Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
Mult Scler. 2017 Sep 1:1352458517731913. doi: 10.1177/1352458517731913.
PubMed Text format Abstract available

GIOVANNONI G, Wiendl H, Turner B, Umans K, et al
Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta.
Mult Scler. 2017 Sep 1:1352458517729464. doi: 10.1177/1352458517729464.
PubMed Text format Abstract available

KAPPOS L, Arnold DL, Bar-Or A, Camm AJ, et al
Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.
Mult Scler. 2017 Sep 1:1352458517728343. doi: 10.1177/1352458517728343.
PubMed Text format Abstract available

BISECCO A, Nardo FD, Docimo R, Caiazzo G, et al
Fatigue in multiple sclerosis: The contribution of resting-state functional connectivity reorganization.
Mult Scler. 2017 Sep 1:1352458517730932. doi: 10.1177/1352458517730932.
PubMed Text format Abstract available

CHARVET LE, Dobbs B, Shaw MT, Bikson M, et al
Remotely supervised transcranial direct current stimulation for the treatment of fatigue in multiple sclerosis: Results from a randomized, sham-controlled trial.
Mult Scler. 2017 Sep 1:1352458517732842. doi: 10.1177/1352458517732842.
PubMed Text format Abstract available

August 2017

BRUNDIN L, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Sweden.
Mult Scler. 2017;23.
PubMed Text format Abstract available

BATTAGLIA M, Kobelt G, Ponzio M, Berg J, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy.
Mult Scler. 2017;23.
PubMed Text format Abstract available

BERGER T, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Austria.
Mult Scler. 2017;23.
PubMed Text format Abstract available

DUBOIS B, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Belgium.
Mult Scler. 2017;23.
PubMed Text format Abstract available

OREJA-GUEVARA C, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain.
Mult Scler. 2017;23.
PubMed Text format Abstract available

CALABRESE P, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Switzerland.
Mult Scler. 2017;23.
PubMed Text format Abstract available

UITDEHAAG B, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands.
Mult Scler. 2017;23.
PubMed Text format Abstract available

FLACHENECKER P, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany.
Mult Scler. 2017;23.
PubMed Text format Abstract available

KOBELT G, Eriksson J, Phillips G, Berg J, et al
The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms.
Mult Scler. 2017;23.
PubMed Text format Abstract available

PENTEK M, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary.
Mult Scler. 2017;23.
PubMed Text format Abstract available

BOYKO A, Kobelt G, Berg J, Boyko O, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia.
Mult Scler. 2017;23.
PubMed Text format Abstract available

RASMUSSEN PV, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Denmark.
Mult Scler. 2017;23.
PubMed Text format Abstract available

LEBRUN-FRENAY C, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for France.
Mult Scler. 2017;23.
PubMed Text format Abstract available

THOMPSON A, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom.
Mult Scler. 2017;23.
PubMed Text format Abstract available

SELMAJ K, Kobelt G, Berg J, Orlewska E, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Poland.
Mult Scler. 2017;23.
PubMed Text format Abstract available

SA MJ, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Portugal.
Mult Scler. 2017;23.
PubMed Text format Abstract available

HAVRDOVA E, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic.
Mult Scler. 2017;23.
PubMed Text format Abstract available

VERMOHLEN V, Schiller P, Schickendantz S, Drache M, et al
Hippotherapy for patients with multiple sclerosis: A multicenter randomized controlled trial (MS-HIPPO).
Mult Scler. 2017 Aug 1:1352458517721354. doi: 10.1177/1352458517721354.
PubMed Text format Abstract available

RUHRMANN S, Ewing E, Piket E, Kular L, et al
Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes.
Mult Scler. 2017 Aug 1:1352458517721356. doi: 10.1177/1352458517721356.
PubMed Text format Abstract available

LAROCCA NG, Hudson LD, Rudick R, Amtmann D, et al
The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.
Mult Scler. 2017 Aug 1:1352458517723718. doi: 10.1177/1352458517723718.
PubMed Text format Abstract available

VAVASOUR IM, Huijskens SC, Li DK, Traboulsee AL, et al
Global loss of myelin water over 5 years in multiple sclerosis normal-appearing white matter.
Mult Scler. 2017 Aug 1:1352458517723717. doi: 10.1177/1352458517723717.
PubMed Text format Abstract available

BERGAMASCHI R, Cortese A, Pichiecchio A, Berzolari FG, et al
Air pollution is associated to the multiple sclerosis inflammatory activity as measured by brain MRI.
Mult Scler. 2017 Aug 1:1352458517726866. doi: 10.1177/1352458517726866.
PubMed Text format Abstract available

SEHR T, Proschmann U, Thomas K, Ziemssen T, et al
Letter to the editor on the paper: "The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".
Mult Scler. 2017 Aug 1:1352458517726384. doi: 10.1177/1352458517726384.
PubMed Text format

LOUAPRE C, Govindarajan ST, Gianni C, Madigan N, et al
Heterogeneous pathological processes account for thalamic degeneration in multiple sclerosis: Insights from 7 T imaging.
Mult Scler. 2017 Aug 1:1352458517726382. doi: 10.1177/1352458517726382.
PubMed Text format Abstract available

SELLEBJERG F, Bornsen L, Ammitzboll C, Nielsen JE, et al
Defining active progressive multiple sclerosis.
Mult Scler. 2017 Aug 1:1352458517726592. doi: 10.1177/1352458517726592.
PubMed Text format Abstract available

ZIMMER P, Bloch W, Schenk A, Oberste M, et al
High-intensity interval exercise improves cognitive performance and reduces matrix metalloproteinases-2 serum levels in persons with multiple sclerosis: A randomized controlled trial.
Mult Scler. 2017 Aug 1:1352458517728342. doi: 10.1177/1352458517728342.
PubMed Text format Abstract available

LEURS CE, van Kempen ZL, Dekker I, Balk LJ, et al
Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.
Mult Scler. 2017 Aug 1:1352458517726381. doi: 10.1177/1352458517726381.
PubMed Text format Abstract available

SOLOMON AJ, Watts R, Ontaneda D, Absinta M, et al
Diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.
Mult Scler. 2017 Aug 1:1352458517726383. doi: 10.1177/1352458517726383.
PubMed Text format Abstract available

AFOLABI D, Albor C, Zalewski L, Altmann DR, et al
Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.
Mult Scler. 2017 Aug 1:1352458517726380. doi: 10.1177/1352458517726380.
PubMed Text format Abstract available

FAISSNER S, Mahjoub Y, Mishra M, Haupeltshofer S, et al
Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?
Mult Scler. 2017 Aug 1:1352458517728811. doi: 10.1177/1352458517728811.
PubMed Text format Abstract available

KALINCIK T, Jokubaitis V, Spelman T, Horakova D, et al
Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis.
Mult Scler. 2017 Aug 1:1352458517728812. doi: 10.1177/1352458517728812.
PubMed Text format Abstract available

BOVE R, Chitnis T, Cree BA, Tintore M, et al
SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.
Mult Scler. 2017 Aug 1:1352458517726657. doi: 10.1177/1352458517726657.
PubMed Text format Abstract available

GIOVANNONI G, Soelberg Sorensen P, Cook S, Rammohan K, et al
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
Mult Scler. 2017 Aug 1:1352458517727603. doi: 10.1177/1352458517727603.
PubMed Text format Abstract available

July 2017

MIGLIORE S, Curcio G, Couyoumdjian A, Ghazaryan A, et al
Executive functioning in relapsing-remitting multiple sclerosis patients without cognitive impairment: A task-switching protocol.
Mult Scler. 2017 Jul 1:1352458517719149. doi: 10.1177/1352458517719149.
PubMed Text format Abstract available

KJOLHEDE T, Siemonsen S, Wenzel D, Stellmann JP, et al
Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis?
Mult Scler. 2017 Jul 1:1352458517722645. doi: 10.1177/1352458517722645.
PubMed Text format Abstract available

TANAKA M, Kinoshita M, Tanaka K
Intermittent drug holidays in fingolimod therapy for multiple sclerosis.
Mult Scler. 2017 Jul 1:1352458517722647. doi: 10.1177/1352458517722647.
PubMed Text format

RODRIGUEZ-LEAL FA, Haase R, Thomas K, Eisele JC, et al
Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?
Mult Scler. 2017 Jul 1:1352458517720043. doi: 10.1177/1352458517720043.
PubMed Text format Abstract available

STAMPANONI BASSI M, Leocani L, Comi G, Iezzi E, et al
Can pharmacological manipulation of LTP favor the effects of motor rehabilitation in multiple sclerosis?
Mult Scler. 2017 Jul 1:1352458517721358. doi: 10.1177/1352458517721358.
PubMed Text format Abstract available

ROLF L, Muris AH, Mathias A, Du Pasquier R, et al
Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis.
Mult Scler. 2017 Jul 1:1352458517722646. doi: 10.1177/1352458517722646.
PubMed Text format Abstract available

BALDASSARI LE, Salter AR, Longbrake EE, Cross AH, et al
Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS.
Mult Scler. 2017 Jul 1:1352458517721357. doi: 10.1177/1352458517721357.
PubMed Text format Abstract available

DUNN N, Juto A, Ryner M, Manouchehrinia A, et al
Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies.
Mult Scler. 2017 Jul 1:1352458517720044. doi: 10.1177/1352458517720044.
PubMed Text format Abstract available

CANCELLI A, Cottone C, Giordani A, Migliore S, et al
Personalized, bilateral whole-body somatosensory cortex stimulation to relieve fatigue in multiple sclerosis.
Mult Scler. 2017 Jul 1:1352458517720528. doi: 10.1177/1352458517720528.
PubMed Text format Abstract available

June 2017

CHOI IY, Lee P, Adany P, Hughes AJ, et al
In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517711568. doi: 10.1177/1352458517711568.
PubMed Text format Abstract available

SATTARNEZHAD N, Farrow S, Kimbrough D, Glanz B, et al
Agreement analysis comparing iPad LCVA and Sloan testing in multiple sclerosis patients.
Mult Scler. 2017 Jun 1:1352458517713667. doi: 10.1177/1352458517713667.
PubMed Text format Abstract available

LEE H, Nakamura K, Narayanan S, Brown R, et al
Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517715811. doi: 10.1177/1352458517715811.
PubMed Text format Abstract available

BOESEN MS, Magyari M, Koch-Henriksen N, Thygesen LC, et al
Pediatric-onset multiple sclerosis and other acquired demyelinating syndromes of the central nervous system in Denmark during 1977-2015: A nationwide population-based incidence study.
Mult Scler. 2017 Jun 1:1352458517713669. doi: 10.1177/1352458517713669.
PubMed Text format Abstract available

PAKPOOR J, Seminatore B, Graves JS, Schreiner T, et al
Dietary factors and pediatric multiple sclerosis: A case-control study.
Mult Scler. 2017 Jun 1:1352458517713343. doi: 10.1177/1352458517713343.
PubMed Text format Abstract available

SALMEN A
Clinical commentary on "Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab".
Mult Scler. 2017 Jun 1:1352458517717810. doi: 10.1177/1352458517717810.
PubMed Text format

MULERO P, Auger C, Parolin L, Fonseca E, et al
Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab.
Mult Scler. 2017 Jun 1:1352458517711569. doi: 10.1177/1352458517711569.
PubMed Text format Abstract available

FOLEY RW, Tagg NT, Schindler MK, Fenton KM, et al
Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517702533. doi: 10.1177/1352458517702533.
PubMed Text format Abstract available

DOBRYAKOVA E, Hulst HE, Spirou A, Chiaravalloti ND, et al
Fronto-striatal network activation leads to less fatigue in multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517717087. doi: 10.1177/1352458517717087.
PubMed Text format Abstract available

RANGANATHAN U, Kaunzner U, Foster S, Vartanian T, et al
Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517719152. doi: 10.1177/1352458517719152.
PubMed Text format

YAP SM, McNicholas N, Hutchinson M, McGuigan C, et al
Immediate thrombocytopenia at time of alemtuzumab infusion for multiple sclerosis - Not always self-limiting, fully reversible or predictable.
Mult Scler. 2017 Jun 1:1352458517719151. doi: 10.1177/1352458517719151.
PubMed Text format

WEYGANDT M, Wakonig K, Behrens J, Meyer-Arndt L, et al
Brain activity, regional gray matter loss, and decision-making in multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517717089. doi: 10.1177/1352458517717089.
PubMed Text format Abstract available

HIDALGO DE LA CRUZ M, d'Ambrosio A, Valsasina P, Pagani E, et al
Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517717807. doi: 10.1177/1352458517717807.
PubMed Text format Abstract available

RUANO L, Branco M, Portaccio E, Goretti B, et al
Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study.
Mult Scler. 2017 Jun 1:1352458517717341. doi: 10.1177/1352458517717341.
PubMed Text format Abstract available

BOZ C, Terzi M, Zengin Karahan S, Sen S, et al
Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517717806. doi: 10.1177/1352458517717806.
PubMed Text format Abstract available

May 2017

VAN KEMPEN ZL, Leurs CE, Witte BI, de Vries A, et al
The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.
Mult Scler. 2017 May 1:1352458517708464. doi: 10.1177/1352458517708464.
PubMed Text format Abstract available

GOVEROVER Y, Chiaravalloti N, Genova H, DeLuca J, et al
A randomized controlled trial to treat impaired learning and memory in multiple sclerosis: The self-GEN trial.
Mult Scler. 2017 May 1:1352458517709955. doi: 10.1177/1352458517709955.
PubMed Text format Abstract available

BENEDICT RH, Cohan S, Lynch SG, Riester K, et al
Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
Mult Scler. 2017 May 1:1352458517707345. doi: 10.1177/1352458517707345.
PubMed Text format Abstract available

FREILICH J, Manouchehrinia A, Trusheim M, Baird LG, et al
Characterization of annual disease progression of multiple sclerosis patients: A population-based study.
Mult Scler. 2017 May 1:1352458517706252. doi: 10.1177/1352458517706252.
PubMed Text format Abstract available

ZEYDAN B, Lowe VJ, Schwarz CG, Przybelski SA, et al
Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis.
Mult Scler. 2017 May 1:1352458517707346. doi: 10.1177/1352458517707346.
PubMed Text format Abstract available

SHINODA K, Matsushita T, Nakamura Y, Masaki K, et al
HLA-DRB1*04:05 allele is associated with intracortical lesions on three-dimensional double inversion recovery images in Japanese patients with multiple sclerosis.
Mult Scler. 2017 May 1:1352458517707067. doi: 10.1177/1352458517707067.
PubMed Text format Abstract available

SALTER A, Thomas NP, Tyry T, Cutter GR, et al
A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry.
Mult Scler. 2017 May 1:1352458517711274. doi: 10.1177/1352458517711274.
PubMed Text format Abstract available

SUMOWSKI JF, Leavitt VM, Rocca MA, Inglese M, et al
Mesial temporal lobe and subcortical grey matter volumes differentially predict memory across stages of multiple sclerosis.
Mult Scler. 2017 May 1:1352458517708873. doi: 10.1177/1352458517708873.
PubMed Text format Abstract available

CAWLEY N, Tur C, Prados F, Plantone D, et al
Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis.
Mult Scler. 2017 May 1:1352458517709954. doi: 10.1177/1352458517709954.
PubMed Text format Abstract available

BALK LJ, Coric D, Nij Bijvank JA, Killestein J, et al
Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis.
Mult Scler. 2017 May 1:1352458517708463. doi: 10.1177/1352458517708463.
PubMed Text format Abstract available

PRINEAS JW, Parratt JDE
Multiple sclerosis: Serum anti-CNS autoantibodies.
Mult Scler. 2017 May 1:1352458517706037. doi: 10.1177/1352458517706037.
PubMed Text format Abstract available

PALOTAI M, Mike A, Cavallari M, Strammer E, et al
Changes to the septo-fornical area might play a role in the pathogenesis of anxiety in multiple sclerosis.
Mult Scler. 2017 May 1:1352458517711273. doi: 10.1177/1352458517711273.
PubMed Text format Abstract available

MARINO M, Frisullo G, Di Sante G, Samengo DM, et al
Low reliability of anti-KIR4.183-120 peptide auto-antibodies in multiple sclerosis patients.
Mult Scler. 2017 May 1:1352458517711275. doi: 10.1177/1352458517711275.
PubMed Text format Abstract available

REDONDO J, Sarkar P, Kemp K, Virgo PF, et al
Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro.
Mult Scler. 2017 May 1:1352458517711276. doi: 10.1177/1352458517711276.
PubMed Text format Abstract available

BIBERACHER V, Schmidt P, Selter RC, Pernpeinter V, et al
Fatigue in multiple sclerosis: Associations with clinical, MRI and CSF parameters.
Mult Scler. 2017 May 1:1352458517712078. doi: 10.1177/1352458517712078.
PubMed Text format Abstract available

SMOOT K, Spinelli KJ, Stuchiner T, Lucas L, et al
Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center.
Mult Scler. 2017 May 1:1352458517709956. doi: 10.1177/1352458517709956.
PubMed Text format Abstract available

TORTORELLA C, Direnzo V, Ruggieri M, Zoccolella S, et al
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis.
Mult Scler. 2017 May 1:1352458517711774. doi: 10.1177/1352458517711774.
PubMed Text format Abstract available

VAN DER VUURST DE VRIES RM, van den Dorpel JJ, Mescheriakova JY, Runia TF, et al
Fatigue after a first attack of suspected multiple sclerosis.
Mult Scler. 2017 May 1:1352458517709348. doi: 10.1177/1352458517709348.
PubMed Text format Abstract available

VAN DEN AKKER LE, Beckerman H, Collette EH, Twisk JW, et al
Cognitive behavioral therapy positively affects fatigue in patients with multiple sclerosis: Results of a randomized controlled trial.
Mult Scler. 2017 May 1:1352458517709361. doi: 10.1177/1352458517709361.
PubMed Text format Abstract available

HEINE M, Verschuren O, Hoogervorst EL, van Munster E, et al
Does aerobic training alleviate fatigue and improve societal participation in patients with multiple sclerosis? A randomized controlled trial.
Mult Scler. 2017 May 1:1352458517696596. doi: 10.1177/1352458517696596.
PubMed Text format Abstract available

BLIKMAN LJ, van Meeteren J, Twisk JW, de Laat FA, et al
Effectiveness of energy conservation management on fatigue and participation in multiple sclerosis: A randomized controlled trial.
Mult Scler. 2017 May 1:1352458517702751. doi: 10.1177/1352458517702751.
PubMed Text format Abstract available

KAPPOS L, Butzkueven H, Wiendl H, Spelman T, et al
Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.
Mult Scler. 2017 May 1:1352458517709619. doi: 10.1177/1352458517709619.
PubMed Text format Abstract available

SORMANI MP
Why non-inferiority is more challenging than superiority?
Mult Scler. 2017;23:790-791.
PubMed Text format Abstract available

HOEPNER R, Kolb EM, Dahlhaus S, Hellwig K, et al
Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.
Mult Scler. 2017;23:830-835.
PubMed Text format Abstract available

NETRAVATHI M, Saini J, Mahadevan A, Hari-Krishna B, et al
Is pruritus an indicator of aquaporin-positive neuromyelitis optica?
Mult Scler. 2017;23:810-817.
PubMed Text format Abstract available

PITTERI M, Romualdi C, Magliozzi R, Monaco S, et al
Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study.
Mult Scler. 2017;23:848-854.
PubMed Text format Abstract available

April 2017

AL-LOUZI O, Button J, Newsome SD, Calabresi PA, et al
Retrograde trans-synaptic visual pathway degeneration in multiple sclerosis: A case series.
Mult Scler. 2017 Apr 1:1352458516679035. doi: 10.1177/1352458516679035.
PubMed Text format Abstract available

SIGNORI A, Izquierdo G, Lugaresi A, Hupperts R, et al
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.
Mult Scler. 2017 Apr 1:1352458517703800. doi: 10.1177/1352458517703800.
PubMed Text format Abstract available

SOLARI A, Giordano A, Patti F, Grasso MG, et al
Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis.
Mult Scler. 2017 Apr 1:1352458517704078. doi: 10.1177/1352458517704078.
PubMed Text format Abstract available

COHEN JA, Imrey PB, Planchon SM, Bermel RA, et al
Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.
Mult Scler. 2017 Apr 1:1352458517703802. doi: 10.1177/1352458517703802.
PubMed Text format Abstract available

GIOVANNONI G, Tomic D, Bright JR, Havrdova E, et al
"No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.
Mult Scler. 2017 Apr 1:1352458517703193. doi: 10.1177/1352458517703193.
PubMed Text format Abstract available

MORANDI E, Tarlinton RE, Tanasescu R, Gran B, et al
Human endogenous retroviruses and multiple sclerosis: Causation, association, or after-effect?
Mult Scler. 2017 Apr 1:1352458517704711. doi: 10.1177/1352458517704711.
PubMed Text format Abstract available

KLAUSER AM, Wiebenga OT, Eijlers AJ, Schoonheim MM, et al
Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis.
Mult Scler. 2017 Apr 1:1352458517702534. doi: 10.1177/1352458517702534.
PubMed Text format Abstract available

AMATO MP
The diagnostic dilemma of multiple sclerosis presenting with isolated cognitive and behavioral disorders.
Mult Scler. 2017 Apr 1:1352458517705002. doi: 10.1177/1352458517705002.
PubMed Text format Abstract available

ZAMBON AA, Cecchetti G, Caso F, Santangelo R, et al
Primary progressive multiple sclerosis presenting with severe predominant cognitive impairment and psychiatric symptoms: A challenging case.
Mult Scler. 2017 Apr 1:1352458517702550. doi: 10.1177/1352458517702550.
PubMed Text format Abstract available

CIAMPI E, Uribe-San-Martin R, Godoy-Santin J, Cruz JP, et al
Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients.
Mult Scler. 2017 Apr 1:1352458517702968. doi: 10.1177/1352458517702968.
PubMed Text format Abstract available

POP R, Kipfer S
Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis.
Mult Scler. 2017 Apr 1:1352458517702535. doi: 10.1177/1352458517702535.
PubMed Text format Abstract available

PAREES I
Clinical commentary on "Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis" and "Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients".
Mult Scler. 2017 Apr 1:1352458517702555. doi: 10.1177/1352458517702555.
PubMed Text format Abstract available

BODINI B, Branzoli F, Poirion E, Garcia-Lorenzo D, et al
Dysregulation of energy metabolism in multiple sclerosis measured in vivo with diffusion-weighted spectroscopy.
Mult Scler. 2017 Apr 1:1352458517698249. doi: 10.1177/1352458517698249.
PubMed Text format Abstract available

KOLBER P, Droby A, Roebroeck A, Goebel R, et al
A "kissing lesion": In-vivo 7T evidence of meningeal inflammation in early multiple sclerosis.
Mult Scler. 2017 Apr 1:1352458516683267. doi: 10.1177/1352458516683267.
PubMed Text format Abstract available

KILSDONK ID, Schoonheim M, Wattjes MP
In-vivo imaging of meningeal inflammation in multiple sclerosis: Presence of evidence or evidence of presence?
Mult Scler. 2017 Apr 1:1352458517704924. doi: 10.1177/1352458517704924.
PubMed Text format

TOUSSAINT-DUYSTER LC, Wong YYM, Van der Cammen-van Zijp MH, Van Pelt-Gravesteijn D, et al
Fatigue and physical functioning in children with multiple sclerosis and acute disseminated encephalomyelitis.
Mult Scler. 2017 Apr 1:1352458517706038. doi: 10.1177/1352458517706038.
PubMed Text format Abstract available

HAGENS MH, Killestein J, Yaqub MM, van Dongen GA, et al
Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study.
Mult Scler. 2017 Apr 1:1352458517704507. doi: 10.1177/1352458517704507.
PubMed Text format Abstract available

SORMANI MP
Indirect comparisons of treatment effects: Network meta-analyses.
Mult Scler. 2017;23:510-512.
PubMed Text format Abstract available

BOUDOT DE LA MOTTE M, Louapre C, Bertrand A, Reach P, et al
Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
Mult Scler. 2017;23:614-616.
PubMed Text format Abstract available

AIRAS L, Rissanen E, Rinne J
Imaging of microglial activation in MS using PET: Research use and potential future clinical application.
Mult Scler. 2017;23:496-504.
PubMed Text format Abstract available

HUM S, Lapierre Y, Scott SC, Duquette P, et al
Trajectory of MS disease course for men and women over three eras.
Mult Scler. 2017;23:534-545.
PubMed Text format Abstract available

D'SOUZA M, Yaldizli O, John R, Vogt DR, et al
Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study.
Mult Scler. 2017;23:597-603.
PubMed Text format Abstract available

VERMERSCH P, Hobart J, Dive-Pouletty C, Bozzi S, et al
Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?
Mult Scler. 2017;23:604-613.
PubMed Text format Abstract available

CIAMPI E, Pareto D, Sastre-Garriga J, Vidal-Jordana A, et al
Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
Mult Scler. 2017;23:556-566.
PubMed Text format Abstract available

BROWNLEE WJ, Altmann DR, Alves Da Mota P, Swanton JK, et al
Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome.
Mult Scler. 2017;23:665-674.
PubMed Text format Abstract available

SORMANI MP, Kappos L, Radue EW, Cohen J, et al
Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS.
Mult Scler. 2017;23:656-664.
PubMed Text format Abstract available

COETZEE T, Thompson A
When are we going to take modifiable risk factors more seriously in multiple sclerosis?
Mult Scler. 2017;23:494-495.
PubMed Text format

March 2017

FEINSTEIN A, Pavisian B
Multiple sclerosis and suicide.
Mult Scler. 2017 Mar 1:1352458517702553. doi: 10.1177/1352458517702553.
PubMed Text format Abstract available

ASGARI N, Jarius S, Laustrup H, Skejoe HP, et al
Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study.
Mult Scler. 2017 Mar 1:1352458517699791. doi: 10.1177/1352458517699791.
PubMed Text format Abstract available

CHARVET LE, Shaw M, Frontario A, Langdon D, et al
Cognitive impairment in pediatric-onset multiple sclerosis is detected by the Brief International Cognitive Assessment for Multiple Sclerosis and computerized cognitive testing.
Mult Scler. 2017 Mar 1:1352458517701588. doi: 10.1177/1352458517701588.
PubMed Text format Abstract available

HOUTCHENS MK, Zapata LB, Curtis KM, Whiteman MK, et al
Contraception for women with multiple sclerosis: Guidance for healthcare providers.
Mult Scler. 2017 Mar 1:1352458517701314. doi: 10.1177/1352458517701314.
PubMed Text format Abstract available

RUGGIERI S, Fanelli F, Castelli L, Petsas N, et al
Lesion symptom map of cognitive-postural interference in multiple sclerosis.
Mult Scler. 2017 Mar 1:1352458517701313. doi: 10.1177/1352458517701313.
PubMed Text format Abstract available

TOURBAH A, Sedel F
Reply to the letter: Biotinidase deficiency masquerading as multiple sclerosis?
Mult Scler. 2017 Mar 1:1352458517702554. doi: 10.1177/1352458517702554.
PubMed Text format

WOLF B
Biotinidase deficiency masquerading as multiple sclerosis?
Mult Scler. 2017 Mar 1:1352458517702551. doi: 10.1177/1352458517702551.
PubMed Text format

GYLLENSTEN H, Wiberg M, Alexanderson K, Friberg E, et al
Comparing costs of illness of multiple sclerosis in three different years: A population-based study.
Mult Scler. 2017 Mar 1:1352458517702549. doi: 10.1177/1352458517702549.
PubMed Text format Abstract available

INEICHEN BV, Schneider MP, Hlavica M, Hagenbuch N, et al
High EDSS can predict risk for upper urinary tract damage in patients with multiple sclerosis.
Mult Scler. 2017 Mar 1:1352458517703801. doi: 10.1177/1352458517703801.
PubMed Text format Abstract available

SORMANI MP
Prognostic factors versus markers of response to treatment versus surrogate endpoints: Three different concepts.
Mult Scler. 2017;23:378-381.
PubMed Text format Abstract available

HUH SY, Kim SH, Hyun JW, Jeong IH, et al
Short segment myelitis as a first manifestation of neuromyelitis optica spectrum disorders.
Mult Scler. 2017;23:413-419.
PubMed Text format Abstract available

GRAVES JS, Chohan H, Cedars B, Arnow S, et al
Sex differences and subclinical retinal injury in pediatric-onset MS.
Mult Scler. 2017;23:447-455.
PubMed Text format Abstract available

ARRAMBIDE G
Commentary on "Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis".
Mult Scler. 2017;23:486-487.
PubMed Text format

February 2017

BACCHETTA F, Mathias A, Schluep M, Du Pasquier R, et al
Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
Mult Scler. 2017;23:300-303.
PubMed Text format Abstract available

HAMID SH, Elsone L, Mutch K, Solomon T, et al
The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates.
Mult Scler. 2017;23:228-233.
PubMed Text format Abstract available

SORMANI MP, Bruzzi P
Estimating a treatment effect: Choosing between relative and absolute measures.
Mult Scler. 2017;23:197-200.
PubMed Text format Abstract available

SORMANI MP, Muraro PA, Saccardi R, Mancardi G, et al
NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
Mult Scler. 2017;23:201-204.
PubMed Text format Abstract available

HULST HE, Thompson AJ, Geurts JJ
The measure tells the tale: Clinical outcome measures in multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517690825. doi: 10.1177/1352458517690825.
PubMed Text format

ROVIRA A
Peripheral nervous system involvement in multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517693469. doi: 10.1177/1352458517693469.
PubMed Text format

January 2017

AMATO MP, Derfuss T, Hemmer B, Liblau R, et al
Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop.
Mult Scler. 2017 Jan 6:1352458516686847. doi: 10.1177/1352458516686847.
PubMed Text format Abstract available

DECARD BF, Thone J, Haghikia A, Bornke C, et al
Listeria rhombencephalitis mimicking a demyelinating event in an immunocompetent young patient.
Mult Scler. 2017;23:123-125.
PubMed Text format Abstract available

GIRARD B, Bonnemains C, Schmitt E, Raffo E, et al
Biotinidase deficiency mimicking neuromyelitis optica beginning at the age of 4: A treatable disease.
Mult Scler. 2017;23:119-122.
PubMed Text format Abstract available

LAROCHELLE C, Metz I, Lecuyer MA, Terouz S, et al
Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal.
Mult Scler. 2017;23:72-81.
PubMed Text format Abstract available

BURTON JM, Eliasziw M, Trufyn J, Tung C, et al
A prospective cohort study of vitamin D in optic neuritis recovery.
Mult Scler. 2017;23:82-93.
PubMed Text format Abstract available

HAAS J, Schneider K, Schwarz A, Korporal-Kuhnke M, et al
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
Mult Scler. 2017;23:114-118.
PubMed Text format Abstract available

KALINCIK T, Sormani MP
Reporting treatment outcomes in observational data: A fine balance.
Mult Scler. 2017;23:21-22.
PubMed Text format Abstract available

SORMANI MP
Subgroup analysis in MS trials.
Mult Scler. 2017;23:34-35.
PubMed Text format Abstract available

December 2016

GHEZZI A
Randomized clinical trials (RCTs) in pediatric multiple sclerosis: Are they really necessary?
Mult Scler. 2016 Dec 1:1352458516684025. doi: 10.1177/1352458516684025.
PubMed Text format

September 2016

HENGSTMAN GJ
Controversies in MS: All relapsing multiple sclerosis patients should be managed at a specialist clinic - Combine the best of two worlds!
Mult Scler. 2016 Sep 21. pii: 1352458516670737.
PubMed Text format

October 2015

WILLIS MD, Harding KE, Pickersgill TP, Wardle M, et al
Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.
Mult Scler. 2015 Oct 29. pii: 1352458515614092.
PubMed Text format Abstract available

UDDIN MN, Lebel RM, Seres P, Blevins G, et al
Spin echo transverse relaxation and atrophy in multiple sclerosis deep gray matter: A two-year longitudinal study.
Mult Scler. 2015 Oct 26. pii: 1352458515614091.
PubMed Text format Abstract available

AHLBRECHT J, Martino F, Pul R, Skripuletz T, et al
Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis.
Mult Scler. 2015 Oct 22. pii: 1352458515613641.
PubMed Text format Abstract available

ROCCA MA, Meani A, Riccitelli GC, Colombo B, et al
Abnormal adaptation over time of motor network recruitment in multiple sclerosis patients with fatigue.
Mult Scler. 2015 Oct 22. pii: 1352458515614407.
PubMed Text format Abstract available

HEITMANN H, Biberacher V, Tiemann L, Buck D, et al
Prevalence of neuropathic pain in early multiple sclerosis.
Mult Scler. 2015 Oct 19. pii: 1352458515613643.
PubMed Text format Abstract available

LANZILLO R, Quarantelli M, Pozzilli C, Trojano M, et al
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon beta1a therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
Mult Scler. 2015 Oct 14. pii: 1352458515611222.
PubMed Text format Abstract available

KARAKY M, Alcina A, Fedetz M, Barrionuevo C, et al
The multiple sclerosis-associated regulatory variant rs10877013 affects expression of CYP27B1 and VDR under inflammatory or vitamin D stimuli.
Mult Scler. 2015 Oct 14. pii: 1352458515610208.
PubMed Text format Abstract available

SANDBERG L, Bistrom M, Salzer J, Vagberg M, et al
Vitamin D and axonal injury in multiple sclerosis.
Mult Scler. 2015 Oct 13. pii: 1352458515606986.
PubMed Text format Abstract available

ZECCA C, Disanto G, Sormani MP, Riccitelli GC, et al
Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis.
Mult Scler. 2015 Oct 12. pii: 1352458515599246.
PubMed Text format Abstract available

HEDSTROM AK, Olsson T, Alfredsson L
Smoking is a major preventable risk factor for multiple sclerosis.
Mult Scler. 2015 Oct 12. pii: 1352458515609794.
PubMed Text format Abstract available

LONGBRAKE EE, Ramsbottom MJ, Cantoni C, Ghezzi L, et al
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Mult Scler. 2015 Oct 12. pii: 1352458515608961.
PubMed Text format Abstract available

AKHTAR S, Alroughani R, Ahmed SF, Al-Hashel JY, et al
Prognostic indicators of secondary progression in a paediatric-onset multiple sclerosis cohort in Kuwait.
Mult Scler. 2015 Oct 9. pii: 1352458515608960.
PubMed Text format Abstract available

SIGNORIELLO E, Lanzillo R, Brescia Morra V, Di Iorio G, et al
Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis.
Mult Scler. 2015 Oct 9. pii: 1352458515604381.
PubMed Text format Abstract available

EISELE P, Konstandin S, Griebe M, Szabo K, et al
Heterogeneity of acute multiple sclerosis lesions on sodium (23Na) MRI.
Mult Scler. 2015 Oct 9. pii: 1352458515609430.
PubMed Text format Abstract available

RICCELLI R, Passamonti L, Cerasa A, Nigro S, et al
Individual differences in depression are associated with abnormal function of the limbic system in multiple sclerosis patients.
Mult Scler. 2015 Oct 9. pii: 1352458515606987.
PubMed Text format Abstract available

DEGN M, Modvig S, Dyring-Andersen B, Bonefeld CM, et al
Increased prevalence of lymphoid tissue inducer cells in the cerebrospinal fluid of patients with early multiple sclerosis.
Mult Scler. 2015 Oct 9. pii: 1352458515609795.
PubMed Text format Abstract available

MACDONELL R, Nagels G, Laplaud DA, Pozzilli C, et al
Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
Mult Scler. 2015 Oct 7. pii: 1352458515606809.
PubMed Text format Abstract available

BOVE R, Healy BC, Musallam A, Glanz BI, et al
Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort.
Mult Scler. 2015 Oct 7. pii: 1352458515606211.
PubMed Text format Abstract available

VERCELLINO M, Fenoglio C, Galimberti D, Mattioda A, et al
Progranulin genetic polymorphisms influence progression of disability and relapse recovery in multiple sclerosis.
Mult Scler. 2015 Oct 7. pii: 1352458515610646.
PubMed Text format Abstract available

TILLEMA JM, Hulst HE, Rocca MA, Vrenken H, et al
Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study.
Mult Scler. 2015 Oct 2. pii: 1352458515607650.
PubMed Text format Abstract available

RATZER R, Iversen P, Bornsen L, Dyrby TB, et al
Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis.
Mult Scler. 2015 Oct 2. pii: 1352458515605908.
PubMed Text format Abstract available

KEARNEY H, Miszkiel KA, Yiannakas MC, Altmann DR, et al
Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis.
Mult Scler. 2015 Oct 2. pii: 1352458515604905.
PubMed Text format Abstract available

September 2015

GUTTMANN CR, Rousset M, Roch JA, Hannoun S, et al
Multiple sclerosis lesion formation and early evolution revisited: A weekly high-resolution magnetic resonance imaging study.
Mult Scler. 2015 Sep 11. pii: 1352458515600247.
PubMed Text format Abstract available

MARTINEZ-RODRIGUEZ JE, Cobo-Calvo A, Villar LM, Munteis E, et al
Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis.
Mult Scler. 2015 Sep 11. pii: 1352458515601215.
PubMed Text format Abstract available

UHER T, Horakova D, Tyblova M, Zeman D, et al
Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later.
Mult Scler. 2015 Sep 11. pii: 1352458515601903.
PubMed Text format Abstract available

BINZER S, Stenager E, Binzer M, Kyvik KO, et al
Genetic analysis of the isolated Faroe Islands reveals SORCS3 as a potential multiple sclerosis risk gene.
Mult Scler. 2015 Sep 11. pii: 1352458515602338.
PubMed Text format Abstract available

SIMULA S, Laitinen T, Laitinen TM, Tarkiainen T, et al
Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis.
Mult Scler. 2015 Sep 11. pii: 1352458515604384.
PubMed Text format Abstract available

August 2015

GONSETTE R, Debouverie M, Sindic C, Ferre JC, et al
Pixantrone: a B-cell-depleting immunosuppressant for multiple sclerosis patients with active disease.
Mult Scler. 2015 Aug 18. pii: 1352458515601902.
PubMed Text format Abstract available

BHARGAVA P, Steele SU, Waubant E, Revirajan NR, et al
Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls.
Mult Scler. 2015 Aug 18. pii: 1352458515600248.
PubMed Text format Abstract available

TACCONI P, Peltz MT, Lorefice L, Marrosu MG, et al
Facial synkinesis as a first symptom of multiple sclerosis.
Mult Scler. 2015 Aug 5. pii: 1352458515584415.
PubMed Text format Abstract available

MILLER DM, Bethoux F, Victorson D, Nowinski CJ, et al
Validating Neuro-QoL short forms and targeted scales with people who have multiple sclerosis.
Mult Scler. 2015 Aug 3. pii: 1352458515599450.
PubMed Text format Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: